Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Singer

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|November 5, 2021
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with DupilumabBenjamin Ungar, Jacob W Glickman, Alexandra K Golant, et al.
The Journal of Allergy and Clinical Immunology|November 27, 2015
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonismEmma Guttman-Yassky, Benjamin Ungar, Shinji Noda, et al.
Archives of Dermatological Research|March 13, 2022
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VIHee J Kim, Ester Del Duca, Ana B Pavel, et al.
Journal of the American Academy of Dermatology|January 13, 2021
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot studyHee J Kim, Giselle K Singer, Ester Del Duca, et al.
Angewandte Chemie (International Ed. in English)|April 3, 2024
PyrAtes: Modular Organic Salts with Large Stokes Shifts for Fluo-rescence MicroscopyIakovos Saridakis, Margaux Riomet, Oliver J V Belleza, et al.
The Journal of Allergy and Clinical Immunology|May 20, 2020
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitisBenjamin Ungar, Ana B Pavel, Randall Li, et al.
Archives of Dermatological Research|March 1, 2022
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areataDaniela Mikhaylov, Jacob W Glickman, Ester Del Duca, et al.
Chemical Science|March 12, 2025
Fluorescent PyrAte-(<i>S</i>)-citalopram conjugates enable imaging of the serotonin transporter in living tissueOliver J V Belleza, Iakovos Saridakis, Nadja K Singer, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Hospital Pharmacy|November 4, 2024
Effect of Inpatient Pharmacist-Led Medication Reconciliations on Medication-Related Interventions in Intensive Care Unit Recovery CentersSarah K Singer, Kevin D Betthauser, Alexandra E Barber, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
The Journal of Allergy and Clinical Immunology. in Practice|November 5, 2021
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with DupilumabBenjamin Ungar, Jacob W Glickman, Alexandra K Golant, et al.
The Journal of Allergy and Clinical Immunology|November 27, 2015
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonismEmma Guttman-Yassky, Benjamin Ungar, Shinji Noda, et al.
Archives of Dermatological Research|March 13, 2022
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VIHee J Kim, Ester Del Duca, Ana B Pavel, et al.
Journal of the American Academy of Dermatology|January 13, 2021
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot studyHee J Kim, Giselle K Singer, Ester Del Duca, et al.
Angewandte Chemie (International Ed. in English)|April 3, 2024
PyrAtes: Modular Organic Salts with Large Stokes Shifts for Fluo-rescence MicroscopyIakovos Saridakis, Margaux Riomet, Oliver J V Belleza, et al.
The Journal of Allergy and Clinical Immunology|May 20, 2020
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitisBenjamin Ungar, Ana B Pavel, Randall Li, et al.
Archives of Dermatological Research|March 1, 2022
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areataDaniela Mikhaylov, Jacob W Glickman, Ester Del Duca, et al.
Chemical Science|March 12, 2025
Fluorescent PyrAte-(<i>S</i>)-citalopram conjugates enable imaging of the serotonin transporter in living tissueOliver J V Belleza, Iakovos Saridakis, Nadja K Singer, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Hospital Pharmacy|November 4, 2024
Effect of Inpatient Pharmacist-Led Medication Reconciliations on Medication-Related Interventions in Intensive Care Unit Recovery CentersSarah K Singer, Kevin D Betthauser, Alexandra E Barber, et al.
Pageof 14